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 Celecoxib nanoemulsion (CXB-NE) has been developed as a macrophage 
targeted analgesics by Dr. Janjic and her team at Duquesne University, (Janjic et al, 2018; 
Liu et al, 2020; Saleem et al, 2019b; Vasudeva et al, 2014). The CXB-NE nanoemulsion 
carrying a Nonsteroidal Anti-inflammatory (NSAID) inhibitor of COX-2 activity result in 
a reduction in PGE2 expression in macrophages. Using CXB-NE in rats that have 
peripheral nerve injury constricting the sciatic nerve relieves hypersensitivity, a pain-like 
behavior.  The treatment also decreases inflammation associated with this chronic 
constriction injury (Janjic et al, 2018; Saleem et al, 2019b; Stevens et al, 2019). In this 
project, we evaluated the potential impact of CXB-NE on neuroregeneration. In CCI, the 
injury and inflammation damages nerves, leading to axon degeneration distal from the 
site of injury. While peripheral nerves can regenerate axons, if axonal degeneration 
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continues to occur due to inflammation, then axonal regeneration cannot proceed. 
Ultimately, axonal regeneration can be an important part of nerve recovery, which in 
humans can aid in rehabilitation after injury. Since CXB-NE is able to decrease 
inflammation, we are exploring the effect that CXB-NE has on axonal regeneration in the 
injured sciatic nerve. To analyze this, we are using immunohistochemistry and epi-
fluorescent microscopy to assess the presence of macrophages, Growth Associated 
Protein (GAP-43), and growth cones as detected through F-actin. The results show that 
GAP-43, which naturally increases expression during nerve regenerations is precociously 
activated days earlier than normal when CXB-NE is present.  Furthermore, CXB-NE 
treatment appears to enhance the production of axon growth cones, indicating that 
inhibiting COX2 with the nanoemulsion therapy promotes axon regeneration.  These 
observations will be discussed in the context of other studies on additional infiltrating 
inflammatory cells and changes in gene expression that are evident during nerve injury 
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1.1 Chronic Neuropathic Pain 
 In the United States, there are currently at least 100 million Americans suffering 
from chronic pain (ISAP, 2011). One of the common forms of chronic pain is peripheral 
neuropathy that arises from inflammation after injury to peripheral nerves (Clatworthy et 
al, 1995). Peripheral neuropathy is associated with neuroinflammation, which is 
generated by activation and infiltration of inflammatory cells such as macrophages that 
contain cyclooxygenase-2 (COX-2) (Ji et al, 2016). COX-2 is the key enzyme driving the 
production produce prostaglandins (e.g.PGE-2) that further drives the neuroinflammation 
and hypersensitivity (Bazan et al, 2001; Ren et al, 2008). To treat neuroinflammatory 
pain, systemic drugs have been a most common option. However, the key challenge is 
that neuroinflammation requires to high of a dose to reach at an effective concentration at 
the site of injury. However, that concentration of drug is also evident throughout the 
entire body and can damage other organs. This has caused a drive to generate a more 
targeted treatment approach that is able to deliver drug to where it is needed with a lower, 
overall body burden. Dr. Janjic’s designed targeted delivery strategy with CXB-NE 
achieves effective dose at the site of injury without systemic exposure to high 
concentrations (Janjic et al., 2018).  
 
1.2 Targeted Drug Delivery Engineering 
Many major diseases have a need for a more targeted drug delivery system because of 
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their underlying pathology and the inadequacies of systemic delivery methods. Finding 
alternative methods with a more targeted approach to delivering drugs is a major part of 
many biomedical engineering and pharmaceutical research initiatives. These fields have 
already proposed multiple alternatives that include: microdevices that use cantilevers 
valves to release drugs when a specific, previously determined threshold is met; synthetic 
polymer scaffolds that have macropores that allow drug to be released once placed at the 
area of interest; multi-phasic devices that allow for pulsatile release of a drug; or 
nanoparticles that allow for short-term release of drug through intravenous injections 
(Cheong et al, 2018; Rambhia & Ma, 2015). Although all of these possible drug systems 
have their benefits, our research focuses on the advantages of using of nanomedicines as 
a drug delivery system. Nanomedicines are a recent, but popular drug delivery system 
studied because of their ability to give therapeutic agents in a more controlled, targeted 
manner (Patel & Janjic, 2015; Patra et al, 2018). They offer multiple benefits such as 
their size that gives them ability to move freely within the body and be more readily 
ingested by cells, increased biocompatibility through use of natural polymers, and 
decreased toxicity due to the decreased dosage added to the nanoparticles (Patra et al., 
2018). Considering these, using a nanomedicine approach for drug delivery should 
bypass the problems of systemic delivery, increase the success of drug, and thus making 
the nanomedicines an ideal system for targeted drug delivery in our research. 
 
1.3 Targeted Drug Delivery via Nanoemulsion 
As previously stated, we are using a targeted drug delivery approach that employs a 
drug-loaded nanoemulsion designed by Dr. Jelena Janjic. The nanoemulsion in this paper 
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was invented and produced by Dr. Jelena Janjic as described in previous literature (Janjic 
et al., 2018; Liu et al., 2020; Patel & Janjic, 2015). Dr. Janjic developed celecoxib, a 
COX-2 inhibitor, loaded nanoemulsion (CXB-NE) that is given at a dose that is 2000x 
less than the typical oral dosage (Janjic et al., 2018; Liu et al., 2020; Saleem et al., 
2019b). CXB-NE is able to be administrated at such a low dose because, after 
intravenous injection, circulating monocytes in the bloodstream phagocytose the drug and 
then naturally accumulate at the site of injury (Janjic et al., 2018; Saleem et al., 2019b). 
These monocytes then infiltrate the injured nerve, differentiating into macrophages. 
Within the sciatic nerve, the nanoemulsion laden macrophages produce less PGE2, 
resulting in pain relief and a number of other subtle changes in the neuroinflammatory 
response (Janjic et al., 2018; Saleem et al., 2019b; Stevens et al., 2019). This direct 
delivery through the immune system allows for CXB-NE to avoid high concentration in 
other systems in the body and negates damage to other organs. Another quality of CXB-
NE is that it has fluorescent dye within it that allows for visualization through live-
imaging and fluorescence imaging after tissue staining (Janjic et al, 2013, 2018; Liu et 
al., 2020; Patel & Janjic, 2015; Patel et al, 2013; Saleem et al, 2019b). This enables us to 
track the flow of the nanoemulsion and confirm the success of the mechanism of this 
method of drug delivery. In past experiments, CXB-NE has been shown to have 
successful accumulated and successful reduce the presence of macrophages at the site of 





1.4 Chronic Pain in vivo  
 In order to replicate chronic pain in vivo to continue to experiment with CXB-NE, a 
chronic pain model needs to be used. One such model is chronic constriction injury (CCI) 
(Bennett & Xie, 1988) as applied to the right sciatic nerve of a rat (Vasudeva et al 2014). 
CCI is a technique that involves tying ligatures loosely around the sciatic nerve. These 
ligatures will generate neuroinflammation that leads to hypersensitivity for the right hind-
paw of the rat (Bennett & Xie, 1988; Clatworthy et al., 1995; Vasudeva et al., 2014). This 
hypersensitivity is measured by assessing pain-like behavior through the Von Frey 
mechanical allodynia test (Chaplan et al, 1994; Deuis et al, 2017; Janjic et al., 2018). 
Because of its ability to replicate peripheral neuropathy and to measure changes in pain-
like behavior with CCI, it makes it an ideal model for these studies.  
 
1.5 Immunohistochemical assessment of infiltrating cells and molecular markers 
indicative of nerve regeneration 
 Immunohistochemical assessment of tissue sections of the affected sciatic nerve can 
reveal aspects of the cell biology of the nerve such that different cells and biological 
markers can be identified. We can use fluorescent antibody staining of tissue from un-
injured nerves compared with nerves damaged by CCI and nerves damaged by CCI but 
treated with COX2 inhibiting nanoemulsion. Specific primary antibodies combined with 
paired secondary fluorescent probes allow for the simultaneous assessment of the 
molecular probes by epi-fluorescent microscopy. This assessment allows for the 
visualization and quantification of specific cells, such as macrophages and target proteins 
such as GAP-43 and F-Actin, which are involved with nerve regeneration.   
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Chapter 2  
Introduction 
Peripheral neuropathy is a form of chronic pain that occurs when an axon is not able 
to regenerate due to the high levels of neuroinflammation from nerve injury (Martin et 
al., 2013). Continual inflammation after injury leads to the inability of an axon to recover 
and begins a process that is known as Wallerian Degeneration. Wallerian Degeneration 
occurs through the increased activity of inflammatory cells such as non-myelinating 
Schwann Cells and M1 (pro-inflammatory) macrophages (Gaudet et al, 2011; Huebner et 
al, 2009). With an increased presence of these cells and the inflammatory mediators that 
they produce, the nerve cannot recover and continues to degenerate. After weeks of 
excess neuroinflammation, M1 macrophages eventually shift into M2 (anti-
inflammatory) macrophages and begin to decrease inflammation around the site of injury 
(Saleem et al., 2019b). This decreased inflammation occurs, in part, through a shift in 
macrophage phenotype and allows for myelinating Schwann Cells to align and increase 
axon recovery. So, when inflammation decreases, axon recovery agents become activated 
and allow for regeneration. Based on these observations and the past studies, CXB-NE 
should be able to increase the presence of axon recovery agents because of its ability to 
decrease inflammation. However, to our knowledge there are no studies that show axonal 
regeneration following CXB-NE treatment with targeted delivery by nanoemulsion. 
In order to study axonal regeneration enhancement from CXB-NE, markers 
associated with axonal regeneration need to be visualized and compared across 
conditions.  One such protein is Growth Associated Protein-43 (GAP-43).  GAP-43 is a 
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substrate for protein kinase C, playing a role in neurite formation through interaction with 
actin remodeling; its expression is increased significantly during nerve regeneration 
(Benowitz & Routtenberg, 1987, 1997).  GAP-43 is seen to be suppressed during 
Wallerian Degeneration due to excess of pro-inflammatory mediators. However, once 
this inflammation is decreased, it has been shown to have elevated levels of expression in 
the membrane of the axon during axonal regeneration (Gaudet et al., 2011; Skene & 
Willard, 1981). Another marker of interest are growth cones that protrude from the ends 
of damaged axons at the site of injury and begin to make complete axons that are growing 
toward their natural targets in the lower limb. These growth cones have an abundance of 
F-actin that functions both structurally in the growth cone and as a component of the 
chemo-guidance control of growth. As such, both GAP-43 and F-actin can serve as good 
markers for axon re-growth. Evidence of growth cones is directly representative of 
regeneration (Lopez-Verrilli et al, 2013; Montani & Petrinovic, 2014). Based on this, it is 
hypothesized the enhanced transition from M1 macrophages to M2 macrophages, which 
is supported by CXB-NE after nerve injury, will allow for a subsequent increase in 
expression of GAP-43 and an increase in the number of identified growth cones. If CXB-
NE is able decrease pain-like hypersensitivity as well as promote axonal regeneration, 
then treatments like this may represent a therapy that can help the 100 million Americans 







Materials and Methods 
3.1 Ethical Statement 
 This study was performed in accordance with the guidelines of the Guide for the Care 
and Use of Laboratory Animals of the National Institute of Health, and the Institutional 
Animal Care and Use Committee (IACUC) at Duquesne University approved the animal 
protocol (Protocol 1803-02). All efforts were made to minimize animal suffering and 
number of subjects used. All surgical procedures were performed under isoflurane 
anesthesia. Male Sprague-Dawley rats weighing 250-350 grams were used in this study 
(Hilltop Laboratory Animals, Inc Scottsdale, PA). Rats were maintained on a 12:12 hour 
light-dark cycle and were given ad libitum access to water and purified chow (D10012G, 
Research Diets, Inc., New Brunswick, NJ). Purified chow was used because it has shown 
to reduce non-specific fluorescence caused by plant materials in regular chow; regular 
chow can interfere with the visualization of the near-infrared fluorescence of the 
nanoemulsion (Vasudeva et al., 2014).   
 
3.2 Surgery and Behavioral Timeline; Two study Groups 
 Animals in the study are managed over the course of two to three weeks (Figure 1). 
There were two main groups with 4 surgical conditions per group for this study. The two 
groups were assessed behaviorally for 12-days post-surgery and a separate group that was 
behaviorally assessed for 18-days post-surgery. The 4 surgical conditions in each group 
were (1) naïve (un-operated), (2) CCI with no treatment, (3) CCI ‘vehicle’ treated with 
Drug Free nanoemulsion (DF-NE), and (4) CCI treated with Celecoxib loaded 
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nanoemulsion (CXB-NE). The DF-NE condition is a CCI subject that on day 8 of the 
behavioral timeline received injection of vehicle-nanoemulsion (DF-NE). The CXB-NE 
condition is a CCI subject that on day 8 of the behavioral timeline received injection of 
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C. Von Frey Behavior 
Testing:
B. Chronic Constriction 
Injury:
E. LICOR Live Imaging:
D. Tail Vein Injections:
Drug Present at CCI Site:
Figure 1.  Summary of surgical timeline and corresponding procedures. (A) The timeline of the procedures 
that a rat undergoes during a 12-day and 18-day experiment is shown above. Every two days, the rat’s pain-like 
hypersensitivity was tested via Von Frey filaments (C) starting two days prior to chronic constriction injury 
surgery (Bennett & Xie, 1988) on the right sciatic nerve (B) and finishing on the day of euthanasia. Eight days 
after CCI surgery, drug-free nanoemulsion (DF-NE) or celecoxib nanoemulsion (CXB-NE) is injected via tail 
vein (D).  Live imaging of the fluorescent dye in the nanoemulsion is taken before injection, after injection, three 
days after injection, and nine days after for those in the 18-day experiment (E). At the end of the 12-day 
experiment and 18-day experiment, the rats are euthanized, and their sciatic nerves were collected for 
immunohistochemistry.  B drawing by Robert Hoggard, C photo by Brooke Deal, D process illustration by John 
Pollock & Jelena Janjic, E NIRF photo by Alyssa Brauckmann. 
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3.3 Chronic Constriction Injury as in vivo Chronic Pain Model 
 The chronic constriction injury method developed by Bennett and Xie (1988) is used 
to generate neuropathic pain in the sciatic nerve of rats as previously described (Janjic et 
al., 2018; Saleem et al., 2019b; Vasudeva et al., 2014). Briefly, the surgery involves 
exposing the right sciatic nerve of the rats by making an incision through the skin and 
carefully separating the muscles of the mid-thigh region of right hind limb. Four ligatures 
are tied loosely around the exposed sciatic nerve (Figure 1B) approximately 1 mm apart 
using 4-0 chromic gut suture (Moore Medical, Connecticut). Care was taken to ensure 
that the ligatures were tight enough for the pain model, but not so tight as to cut off 
epineural blood flow (Chen et al, 2020). Once the sutures were optimal around the nerve, 
the incision site was closed by using 9 mm stainless steel auto clips. 
 
3.4 Mechanical Allodynia Testing 
 Behavior testing was performed through assessment of mechanical allodynia with the 
up-down method of applying von Frey filaments to the plantar surface of the hind paw 
(Figure 1C) (Chaplan et al., 1994; Deuis et al., 2017; Janjic et al., 2018; Saleem et al., 
2019b). Before testing begins, the animals were placed on a metal grid that allows access 
to paws with a Plexiglass cover and acclimated for 30 minutes. After acclimating, testing 
occurs in which the left and right hind paws of all the subjects were probed to the point 
where the testing filament bends (Figure 1C), and the rat’s responses were recorded. A 
documented withdrawal is when the rat removed its paw from the filament via lifting its 
paw or lifting and flicking its paw. Testing begins with a median filament. If this 
withdrawal happened, then a next smaller filament is used with a smaller gram force. If 
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this withdrawal did not happen, then the next bigger filament is used. This process 
continues until either of the following happen: the rat withdrawals when the smallest 
filament is used, the rat does not withdrawal when the largest filament is used, or four 
probes after the first change in withdrawal behavior.  
 Baseline behavior was established two days prior to surgery and on the day of surgery 
for all groups. Testing continued every other day starting at day 2 until day 12 for the 12-
day group and until day 18 for the 18-day group. The 50% paw withdrawal threshold was 
calculated using the principle of the median lethal dose (LD50) that determines the 
threshold in grams that the rat will withdrawal its paw 50% of the time (Chaplan et al., 
1994; Janjic et al., 2018; Saleem et al., 2019b). Hypersensitivity is evident when a lower 
threshold force causes paw withdrawal.  Hypersensitivity is interpreted as pain-like 
behavior.  
 
3.5 Rat Tail-Vein Injection of Nanoemulsion and NIRF Live Imaging 
 On day 8 post-surgery, CCI rats begin to reach a plateau of pain-like behavior similar 
to that seen in previous studies (Janjic et al., 2018; Saleem et al., 2019b; Stevens et al., 
2019; Vasudeva et al., 2014). The rats were put under isoflurane anesthesia and live 
NIRF imaging for background of near-infrared fluorescence prior to injection using a 
LiCOR Pearl Impulse (LI-COR Biosciences, Lincoln, NE). The procedure described in 
Saleem et al., 2019a (JoVE) involves warming the tail with water to dilate the veins. 
Using the lateral veins, the needle was placed in the vein without the syringe. Once blood 
flows through the needle gauge, the needle is considered to be successfully placed in vein 
(Saleem et al, 2019a). The syringe is added to the needle gauge and the celecoxib-loaded 
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nanoemulsion (CXB-NE) and the vehicle nanoemulsion (DF-NE) were injected 
intravenously in this vein. The DF-NE was used as a vehicle control. The injection for 
CXB-NE represents a single dose of celecoxib ~0.24 mg/kg. Immediately after injection, 
the rats were imaged on again LiCOR for the near-infrared fluorescence (NIRF) of the 
nanoemulsion. A successful injection was indicated by the nanoemulsion being 
completely cleared from the tail vein except for the possibility of a small spot at the site 
of injection. All injections were successful for this study. NIRF live imaging was 
continued throughout the experiment on day 11 and day 17 (for the 18-day experiment 
only). All of images from the LICOR Imaging system that were to be compared were 
combined with a single linked look-up tables (LUTs) adjusted for brightness and contrast 
of the positive images.  The same LUT was applied to the negative controls and NIRF 
background images.  The LICOR Peal Impulse software gives two mergeable channels 
for visualization: a white light channel for a body view and 785 nm excitation for 820 
emission, which detects the DiD in the nanoemulsion. The relative fluorescence a region 
of interest (ROI) was determined by drawing an ROI over the incision site to get the 
NIRF signal intensity using the LICOR ImageStudioLite Software (version 5.2.5).  A 
comparable background image was also acquired and the relative fluorescence per unit 
area was calculated.  
 
3.6 Euthanasia and Sciatic Nerve Processing 
 At the end of the experiment, the rats were euthanized. The right (ipsilateral 
surgically treated) and left (contralateral control) sciatic nerves were then dissected and 
stored overnight in 4% paraformaldehyde in 1X phosphate-buffered saline (PBS) at 4°C 
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for fixation. For each animal, the contralateral, left leg sciatic nerve was used as control 
for the histology. The next day, the tissues were stored in 30% sucrose overnight. The 
tissues were then placed in optimal cutting compound (OCT) solution for sectioning and 
frozen with a bath of isopentane surrounded by dry ice at a temperature of about ~-55 to -
60°C. The frozen tissues were cut at -20°C, and then sectioned on the cryostat (MICROM 
HM550, MI) at 20 µm, mounted on gelatin-coated slides (SouthernBiotech, Birmingham, 
AL).  Slides were stored at -20°C until immunohistochemical processing was carried out. 
 
3.7 Immunohistochemistry and Nanoemulsion NIRF Detection 
 Tissue sections from each condition underwent equivalent immunohistochemistry 
staining. Briefly the sections for each condition were warmed for 30 minutes on the slide 
warmer and then fixed in 4 % paraformaldehyde for 15 minutes. Then, they went through 
5 washes for 5 minutes each in 1X PBS, permeabilized with 0.3% Triton 1X PBS for 30 
minutes, and blocked with 5 % normal donkey serum (NDS) for one hour. 5% NDS was 
obtained from NDS stock and 1X PBS solution. 
 Two immunostains that were performed. The first stain was an immunostain for the 
presence of macrophages using the primary antibody: mouse monoclonal anti-CD68 
1:500 (MCA341R, Bio-Rad) and secondary antibody: Alexa Fluor 555 goat anti mouse 
(A21127, Invitrogen). The second stain was a double immunostain to reveal the number 
of growth cones (F-Actin) and relative expression of GAP-43 using primary antibodies: 
mouse monoclonal anti-F-actin 1:100 (Ab205, Abcam) and rabbit polyclonal anti-GAP-
43 1:250 (PA1-16729, Invitrogen). The secondary antibodies used for this stain were 
Alexa Fluor 555 goat anti-mouse 1:200 (A21426, Invitrogen) and Alexa Fluor 488 
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donkey anti rabbit 1:200 (A21206, Invitrogen). All of the antibodies were diluted using 
5% NDS in 1X PBS. After both primary and secondary washes, the slides were rinsed 5 
times with 1X PBS. After the washes following the secondary antibody incubation, 
Prolong diamond antifade reagent with DAPI (P36965, Thermo Fisher Scientific) was 
applied to mount the coverslip to the slide.  DAPI is a blue-fluorescent DNA stain that 
exhibits enhanced fluorescence when it is intercalated into A-T rich double stranded 
DNA. As such it is an efficient nuclear stain. A fourth fluorophore detected in some of 
these experiments is the DiR near infrared dye, which is a component of the 
nanoemulsion.  It is detected with the 640 nm laser on the Nikon A1r confocal 
microscope. 
 
3.8 Microscopy and Image Analysis 
 All stained sections were viewed on Nikon NiU Fluorescence Microscope with Nikon 
NIS-Elements imaging software. Using the built-in programs on the Nikon NIS-
Elements, multiple regions of interest (ROIs) were drawn per field of view. In these 
ROIs, the number of growth cones or CD-68 positive macrophages were counted. These 
ROIs and the Nikon NIS-Elements built-in functions also allow for the mean 
fluorescence of GAP-43 to be calculated with a background ROI for normalization. The 
number of growth cones, number of CD-68 positive macrophages and the normalized 
mean fluorescence of GAP-43 for all the ROIs were then used for statistical analysis. For 
higher magnification images, the Nikon A1 confocal microscope equipped with six 
excitation solid-state diode lasers (405 nm, 440 nm, 488 nm, 514 nm, 561 nm, and 
640 nm) was used with image acquisition and processing with the Nikon NIS-Elements 
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software.  Additionally, coincidence of DiR and CD68 staining in macrophages was 
demonstrated by confocal microscopy.  
 
3.9 Statistical Analysis 
 Statistical analysis was done using GraphPad Prism 6 statistical software. Since the 
number of animals per condition in this analysis is one (n=1 per condition in each group), 
statistical analysis was not able to be used for behavior and LiCOR live animal imaging 
data. However, statistical analysis could be made for the stained sections due to the 
multiple ROIs demonstrating the consistency of image analysis in determining the 
relative values for in an individual animal’s infiltration of macrophages, and GAP-43 or 
F-Actin expression in the nerve. The counts for growth cones and macrophages and the 
relative mean-fluorescence for GAP-43 were analyzed using a one-way ANOVA with a 
95% confidence interval and Tukey’s post-hoc test to make multiple comparisons. The 













4.1 Pain-like hypersensitivity differs across treatment groups 
Pain-like hypersensitivity in rats with neuropathic pain caused by CCI was tested 
using Von Frey filaments that measure mechanical allodynia. The mechanical allodynia 
testing allows for the calculation of the withdrawal threshold of the rat’s paw in which 
the lower the threshold, the more pain-like hypersensitivity that rat has. Baseline behavior 
was established two days prior to surgery and the day of surgery; during these pre-
surgery days every group displays the same thresholds and each sub-category represents 
an n=1(Figure 2). The corresponding days following surgery show that DF-NE and CCI 
thresholds are consistently low while naïve remains at baseline threshold throughout the 
duration of the experiments. The changes are seen in CXB-NE after day 8 when CXB-NE 
is injected. In the 12-day experiment, after injection of CXB-NE the rat’s withdrawal 
threshold climbs back to baseline by day 12 (Figure 2a), interpreted as significant pain-
relief. In the 18-day experiment, after injection of CXB-NE the rat’s withdrawal 
threshold partially recovers but did not achieve baseline relief (Figure 2b). The threshold 
at which this CCI CXB-NE Day 18 rat experiences a withdrawal 50% of the times that it 
was probed was higher than that of CCI and CCI DF-NE. This means that the CCI CXB-
NE Day 18 rat was experiencing pain-relief as compared to the pain that the rats 
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Figure 2. Pain-like hypersensitivity behavior testing results for the 12-Day and 18-Day time-points for the 
animals used in the immunohistochemistry experiments presented below.  Mechanical allodynia of the rats was 
measured through the Von Frey behavior test for both the individual 12-day animals used in the IHC (A) and 
individual 18-day animals used in the IHC experiments (B). At day 0, CCI surgery occurs and at day 8, 
nanoemulsion is injected. For both the 12-day and 18-day experiments Naïve, CCI, DF-NE, and CXB-NE n =1. In 
both time-points, the rats in the naïve condition demonstrated no hypersensitivity while the CCI and DF-NE rats had 
continued hypersensitivity after CCI with no relief. In the 12-day experiment, the rat with CXB-NE appears to 
recover back to baseline with no pain-like hypersensitivity while the rat with CXB-NE in the 18-day experiment had 
a very slight recovery, but still demonstrated pain-like hypersensitivity.  (C). Shown are the individual behavioral 
responses for the animals experiencing different treatments 
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4.2 CXB-NE NIRF signal decreased in injured sciatic nerve in live imaging 
 The NIRF signal in the nanoemulsion was detected in live rats by imaging the relative 
fluorescence with a LiCOR Pearl Impulse (LI-COR Biosciences, Lincoln, NE). In 
previous studies, it was shown that the macrophages that contain phagocytosed 
nanoemulsion infiltrate the injured sciatic nerve at a significant quantity by day 11 (Janjic 
et al., 2018; Saleem et al., 2019b; Stevens et al., 2019; Vasudeva et al., 2014). As such 
live animal images for DF-NE and CXB-NE are taken before injection, after injection 
(Figure 3A.1, 3B.1), at day 11 (Figure 3A.2, 3B.2), and again at day 17 for the 18-day 
experiment (Figure 3B.3). After the tail-vein injection, a small circle of the NIRF signal 
can be detected at the site of injection. At day 11, the NIRF can be detected at the sciatic 
nerve. The intensity of the NIRF signal in DF-NE CCI rats is higher than the intensity of 
the CXB-NE’s NIRF signal (Figure 3A.3, 3B.4). This trend is continued to day 17, but 

















Figure 3. LICOR Live Imaging results for 12-Day and 18-Day time-points.  LICOR Live imaging is 
performed before injection of DF-NE and CXB-NE, after injection (A1 and B1), at day 11 (A2 and B2) , 
and at day 17 with one animal for DF-NE and CXB-NE in both the 12-Day and 18-Day experiment (B3) 
compared with linked look-up tables. In each graph, the n=1 such that there is only one DF-NE and one 
CXB-NE. The fluorescence intensity of the NIRF signal at day 11 for the DF-NE condition showed an 
increased fluorescence as compared to CXB-NE (A3 and B4). The fluorescence intensity of the NIRF 
signal at day 17 showed that the intensity appears to decrease for both DF-NE and CXB-NE, but DF-NE 
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4.3 The number of macrophages in injured sciatic nerve is decreased with CXB-NE 
treatment 
 The number of macrophages present in all groups was detected using anti-CD68 
immunohistochemical staining with nuclei staining through DAPI visualized with a 
Nikon NiU Fluorescence Microscope and Nikon Elements imaging software (Figure 4A). 
The average number of macrophages per ROI and its corresponding standard error of the 
mean was calculated for ~28-80 ROIs per condition and the significance between groups 
was calculated (Figure 4B). At both day 12 and day 18, there was a significant increase 
(p-value < 0.0001) in the number of infiltrating macrophages per ROI between Naïve and 
CCI as well as Naïve and DF-NE. However, for animals in pain, there was no significant 
difference between CCI and DF-NE at both day 12 and day 18. There was, however, a 
significant decrease (p-value < 0.0001) in the number of infiltrating macrophages per 
ROI between DF-NE and CXB-NE at both 12-day and 18-day time-points. The presence 
of the NIRF signal in the infiltrating macrophages was visualized by confocal microscopy 











Figure 4. Presence of CD68 positive macrophages. All images were taken with Nikon NiU Fluorescence Microscope with 
Nikon Elements imaging software. Nuclei are highlighted with DAPI.  CD68 reveals infiltrating macrophages at the site of 
injury (A). The scale bar = 100 µm. The images for Naïve, CCI, DF-NE, and CXB-NE tissue conditions in the 12-day 
experiment (A1, A3, A5, A7) and the 18-day experiment (A2, A4, A6, A8), respectively, were used for analysis. Using multiple 
fields of view and about ~28-80 ROIs per tissue condition, the number of macrophages in each ROI were calculated. The 
average number of macrophages per ROI was calculated for each tissue condition and the standard deviation of the mean was 
also calculated which are represented by the error bars (B). There was a significant increase in the number of macrophages from 
Naïve and CCI (**** p-value of <0.0001) as well as DF-NE (**** p-value of <0.0001). There was no significant difference 
between CCI and DF-NE, but there was a significant decrease in the number of macrophages from CCI/DF-NE to CXB-NE 
(**** p-value of <0.0001) (n=1 animal per condition), ~28-80 ROIs, one-way ANOVA with Tukey’s post hoc test).  To show 
that the macrophages had nanoemulsion in them, the NIRF in the nanoemulsion was visualized using confocal microscopy with 
the CD68 and DAPI overlay (C1). A zoomed in image of the macrophage in the box in C1 was taken and the CD68 channel 
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4.4 GAP-43 expression increases with time after CCI;GAP-43 increase in expression is 
accelerated with CXB-NE. 
 The expression of Growth-Associated Protein 43 in all groups was detected using 
anti-GAP-43 immunohistochemistry staining and the Nikon NiU Fluorescence 
Microscope with Nikon Elements imaging software for visualization (Figure 5A). The 
average GAP-43 mean fluorescence per ROI and its corresponding standard error of the 
mean was calculated for ~20-50 ROIs per condition and the significance between groups 
was calculated (Figure 5B). At day 12, there was no significance difference in GAP-43 
expression between naïve and DF-NE. However, there is a significant increase (p-value 
<0.0001) in GAP-43 expression in the DF-NE treated sciatic nerve by day 18. The day 8 
injection of CXB-NE led to the early increase in the expression of GAP-43, evident at 
day 12 instead of day 18. Interestingly, the expression of GAP-43 is significantly reduced 









































Figure 5. GAP-43 protein expression and F-Actin Growth Cones. All images were taken with Nikon NiU 
Fluorescence Microscope with Nikon Elements imaging software (Bar = 100 µm). (A) GAP-43 protein expression 
at the site of injury for Naïve, DF-NE, and CXB-NE 12-day (A1-3) and the 18-day (A4-6). The mean fluorescence 
of ~20-50 ROIs per tissue condition were taken. The fluorescence of each ROI was normalized to background 
fluorescence for each field of view and the average mean fluorescence for each tissue condition was taken along 
with the standard error of the mean (the error bars) (B). There was a significant increase in the mean fluorescence 
of GAP-43 between Naïve and CXB-NE during the day 12 experiment (**** p-value of <0.0001) that isn’t seen 
until day 18 for DF-NE conditions (**** p-value of <0.0001) and there is also a significant decrease (p-value 
<0.01) in GAP-43 expression between Day 12 CXB-NE and Day 18 CXB-NE (n=1 animals per condition, ~20-50 
ROIs, one-way ANOVA with Tukey’s post hoc test). Next, the number of growth cones per ~20-50 ROIs per 
condition were counted. The images for F-Actin were taken on the Nikon A.1 Confocal microscope at the 60X 
objective at the digital 4X zoom with a 50 μm scale bar (C1). A closer look at the growth cones in the box in 
image C1 was taken (C2). The average number of growth cones per condition was calculated with the standard 
deviation of mean (C3). There was a significant increase in the presence of growth cones from Naïve and DF-NE 
to CXB-NE at both Day 12 and Day 18 experiments (n=1 animal per condition, ~20-50 ROIs, **** p-value 
<0.0001, one-way ANOVA with Tukey’s post hoc test).  
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4.5 The number of growth cones in injured sciatic nerve is increased with CXB-NE 
treatment 
 The number of growth cones present in all groups was detected using anti-F-Actin 
immunohistochemistry staining and the Nikon A1r Confocal microscope for visualization 
(Figure 5C.1, 5C.2). The average number of growth cones per ~20-50 ROIs per condition 
and the standard error of the mean was calculated to be used to test for significance 
(Figure 5C.3). There was no significant difference between Naïve and DF-NE conditions 
in both 12-day and 18-day experiments, but there was a significant increase (p-value < 


















5.1 Theranostic nanoemulsion is able to relieve pain-like hypersensitivity in the 12-day 
experiment and decrease inflammation at both day 12 and day 18 
 We hypothesized that after intravenous injection of low-dose celecoxib in a 
nanoemulsion, the circulating monocytes in the blood phagocytose the nanoemulsion. 
These monocytes will then naturally accumulate at the site of injury.  Triggered by 
cytokines produced in the sciatic nerve these infiltrating immune cells differentiate into 
mature macrophages while carrying CXB-NE. This delivers CXB-NE directly to the site 
of injury and allows for the inhibition of the COX-2/PGE2 neuroinflammatory pain 
pathway.  
       The behavioral results for CCI animals treated with CXB-NE during the 12-day 
experiment, were similar to those previously reported by our laboratory further indicating 
the success CXB-NE at decreasing hypersensitivity to be equivalent to the baseline naïve 
control (Janjic et al., 2018; Saleem et al., 2019b). However, this effect was not evident in 
the 18-day CXB-NE rat in this study. The rat displayed the same patterns of behavioral 
hypersensitivity through day 12 in much the same way as the 12-day CXB-NE rat. The 
animal’s walking gait scrunched its toes, general range of motion were all consistent with 
expected behaviors.  The rat was also able to withstand stiffer Von Frey filaments than 
the hypersensitive CCI and DF-NE rats, but did not exhibit the same robust recovery 
evident in the CCI CXB-NE rat studied in the day 12 experiment. All of these 
explanations make the rat an outlier for this study.  
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 However, even though the threshold of behavior were not the same, the decrease in 
infiltration of macrophages in both the 12-day and 18-day CXB-NE rats was consistent 
with what has been previously shown (Saleem et al., 2019b). For both experimental 
conditions of CXB-NE and DF-NE, we also found that the NIRF signal at day 11 for the 
18-day experiment had the same relative intensity as the NIRF signal at day 11 for the 
12-day experiment (Figure 3). This shows that CXB-NE was able to be delivered at the 
same efficiency to the injured nerve. The success of the delivery of CXB-NE to the 
injured nerve clearly reduced the level of inflammation as measured by the number of 
infiltrating macrophages (Figure 4).  The fact that this particular rat in the 18-day study 
did not achieve complete pain relief can be explained in at least two possible ways.  First, 
it is important to recognize that we are assessing a unique individual.  As has been seen in 
previous studies (Janjic et al., 2018 [n=9]; Saleem et al., 2019b [n=7]; Stevens et al., 
2019 [n=5]), this individual’s behavioral response is in the range of behaviors observed 
with CCI CXB-NE rats similarly studied. This behavior is, nonetheless, an outlier and 
needs to be considered with caution.  For example, there is a possibility that for the day-
18 rat, the four chromic gut ligatures may not have been tied with equivalent tension.  A 
recent study explored the variation of behavior that corresponds to loose, normal and 
tight ligatures (Chen, et al, 2020). It reports that the compression force of the ligatures 
will result in differing levels of muscle atrophy in which the tighter the suture, the more 
atrophy. Given this, it is possible that the rats sutures were not loose enough causing 
slight muscle atrophy and therefore displaying the slowed recovery.  
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5.2 Theranostic nanoemulsion is able to increase the presence of markers of axonal 
regeneration  
 The neuroinflammation caused by CCI on the right sciatic of rats is known to 
decrease the ability of axons to regenerate through a process known as Wallerian 
Degeneration (Gaudet et al., 2011; Huebner & Strittmatter, 2009). The mechanisms of 
axonal regeneration are repressed when inflammation is high at the site of injury. This is 
shown through the proposed mechanism of action in which the increase in the presence of 
pro-inflammatory chemicals and macrophages that inhibit expression of GAP-43 and 
therefore production of growth cones (Figure 6A). With CXB-NE, inflammation is 
reduced as evident through the inhibition of the COX-2, the reduction of PGE2, the 
reduction in infiltrating macrophages, as well as the shift in macrophage phenotype and 
the influence on Mast Cell degranulation (Saleem et al., 2019b).  Here we present 
evidence and a possible mechanism of how CXB-NE supports axon regeneration with the 
enhancement of GAP-43 expression earlier than normal as well as an increase in the 
number of growth cones as detected by F-actin expression (Figure 6B).  The immunostain 
results for GAP-43 show that the presence of CXB-NE enhances GAP-43 expression 6 
days before there is a naturally occurring increase in GAP-43 expression as seen in DF-
NE conditions. With the decrease in inflammation by CXB-NE, GAP-43 was able to 
become activated early and may be contributing to the axon recovery days before it 
appears to come on when celecoxib is not present (Figure 6B). The results from the F-
actin stain for growth cones showed that in both 12-day and 18-day experiments, CXB-
NE was able to enhance the formation of growth cones within the fasciculated nerve 
bundle. There are substantially more growth cones that are present in CXB-NE than the 
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other conditions. With the enhancement of both GAP-43 and growth cones when CXB-
NE is present, it is concluded that CXB-NE presence is able to promote and enhance 
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Figure 6. Proposed Mechanism of Action of Chronic Constriction Injury on Sciatic Nerve with and without CXB-
NE Injection. Part A represents the mechanisms of action after chronic constriction injury without injection of CXB-NE. 
Once the sciatic nerve is injured, macrophages become activated to begin cleaning up debris and are predominantly pro-
inflammatory macrophages, M1. Activated macrophages activate COX-2 to produce PGE-2. Prostaglandins will increase 
production Substance P and increase the infiltration of macrophages to the site of injury. Substance P increases 
nociceptor sensitization that leads to the pain-like hypersensitivity experienced with peripheral neuropathy while the 
increase in infiltrating macrophages increases neurogenic inflammation. When there is an increase in the pro-
inflammatory chemicals and macrophages, axonal regeneration agents are inhibited specifically GAP-43. GAP-43 
enhances the development of growth cones, so growth cones development is also inhibited. Overall, chronic constriction 
injury causes increase pain-like hypersensitivity, increased inflammation, and decreased axonal regeneration. Part B 
represents the mechanisms of action after chronic constriction injury with injection of CXB-NE. Once CXB-NE is 
injected and travels to site of injury through differentiated macrophages, Celecoxib binds reversibly and specifically to 
COX-2 within the macrophage. Celecoxib binding causes an inhibition of COX-2 and subsequent inhibition of PGE-2. 
Without PGE-2, M1 macrophages switch to M2, anti-inflammatory macrophages, which decreases nociceptor 
sensitization and inflammation. The decrease inflammation also allows for the activation of axonal regeneration agents 










Limitations and Future Directions 
 A major limitation to this study is that this is a pilot study with only one subject per 
condition. With only having one animal to represent each condition, there is a chance the 
data is due to variation among the individuals. Also, the CCI CXB-NE Day 18 animal did 
not exhibit pain relief behavior back to baseline as is the normal response to the 
nanoemulsion therapy.  As such, this animal is considered an outlier. It is interesting that 
the CXB-NE was able to have an effect on this Day 18 animal as is evident in the 
decrease in the presence of macrophages.  The drug was getting to the site of 
inflammation and was influencing the density of infiltrating macrophages. So, in order to 
overcome this limitation, additional animals need to be included in the study. Care will 
need to be taken to ascertain whether this outlier represents an anomaly or whether this 
individual represents a subset phenotypic behavior.  
 In future studies, they should consider exploring the involvement of other important 
axonal regeneration agents. GAP-43 and growth cones are just two of many important 
agents that contribute to the regeneration of axons. Specific agents of interest are 
Schwann cells, Toll-Like Receptors (TRLs), and laminin trimers. Schwan cells are shown 
to increase axonal regeneration through promoting growth cones, so further 
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characterization of their response to CXB-NE could help to clarify their role in 
supporting the presence of growth cones and regeneration. TRLs are receptors on 
Schwann cells that are used to detect tissue damage. Stevens et al (2019) also showed that 
Toll Like receptor 2 exhibited differential mRNA expression in the CCI DF-NE and CCI 
CXB-NE conditions as compared to sham sciatic nerves as assayed by qPCR.  Finally, 
laminin trimers act directly on neurons and Schwann cells to help with maintenance and 
repair of neurons (Gaudet et al., 2011; Lopez-Verrilli et al., 2013). When laminin 
expression is inhibited, the axon loses its ability to regenerate completely. By analyzing 
such agents, we can further confirm that CXB-NE is enhancing axonal regeneration and 
further understand the mechanism that drives axonal regeneration from CXB-NE 
injection. 
 Another future direction that can be taken is a second dosage of CXB-NE. In past 
studies, it was shown that CXB-NE’s pain relief subsides after 6 days (Saleem et al, 
2019). However, there have been no studies to date showing what happens when CXB-
NE is injected for a second time. In order for this experiment to happen, the second CXB-
NE dosage will need a new NIRF dye to allow for the discrimination of both the original 
and second dosage of CXB-NE.  Through visualizing this, we will be able to determine 
how additional injections affect hypersensitivity, macrophage recruitment, axonal 
regeneration, as well as the effect on other systems within the body. Janjic and colleagues 
have already demonstrated the engineering capability needed to introduce additional NIR 
dyes into a single nanoemulsion (Patel, Patrick, et al., 2013).  This will allow us to further 
understand the mechanisms of peripheral neuropathy after CXB-NE treatment. It will 
also allow us to determine if additional injections will continue to support the repair of 
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axons.  
 A final future direction that can be considered is developing a software routine that 
embraces the capabilities built into the Nikon Elements software that allows for 
measuring relative fluorescence brightness as well as the capability to count objects in a 
field of view or region of interest. The Nikon Elements software has the tools that can be 
trained to identify cells in an image acquired on either the conventional or confocal 
microscopes. The code could be set to determine a threshold for positive staining for the 
agents of interest, such as coincident DAPI (nuclear) and CD68 (macrophage) cell 
identity, which can then be automatically counted. That data can be exported to a file for 
statistical analysis. Once validated, engineering such a code would minimize the hours 
spent counting the targets of interest and allow for more time with other experiments as 


















Chapter 7  
Conclusions 
 Overall, this pilot study provides evidence that the pain-reliving micro-dose of COX2 
inhibiting CXB-NE also enhances the potential for axon outgrowth and nerve 
regeneration.  The assessment of behavior and macrophage infiltration provided further 
confirmation to observations previously reported, that CXB-NE is effective in providing 
pain-relief and reducing inflammation as evident by the infiltration of CD-68 positive 
macrophages (Janjic et al., 2018; Saleem et al., 2019; Stevens et al., 2019b).  Two key 
markers of axon growth and regeneration are enhanced by the presence of CXB-NE; 
GAP-43 and F-actin labeled growth cones. These observations are consistent with 
observation that CXB-NE promotes the transition of M1 macrophage population in the 
injured sciatic nerve to M2 phenotype, which promote repair and regeneration of injured 
tissue (Saleem et al., 2019b).  The increase in GAP-43 expression is also an indicator of 
nerve regeneration, which is evident at day 18 without celecoxib, but appears to be 
enhanced with precocious expression at day 12 when CXB-NE is present. Finally, 
detection of F-actin in a morphology consistent with the visualization of growth cones in 
fasciculated nerve bundles of the sciatic nerve provides compelling evidence for nerve 
regeneration enhancement by localized COX2 inhibition.  This observation is also 
 33 
consistent with the report by Stevens et al (2019) that showed that the expression of actin 
mRNA in the injured sciatic nerve is significantly enhanced by CXB-NE. 
Taken together, these results indicate that CXB-NE is able to promote axonal 
regeneration after CCI injury.  
 By confirming that CXB-NE contributes to supporting axon regeneration, we can 
consider the use of nanoemulsion delivered NSAID that not only provide chronic pain 
relief but may also be effective in aiding regenerating the damaged nerve leading to 
eventual axon recovery. Relieving pain and promoting nerve regeneration may provide an 
important alternative to opioids which treat an aspect of pain but does not contribute to 
healing.  Success could help to diminish the opioid crisis in America and significantly 




















Bazan, N. G. (2001). COX-2 as a multifunctional neuronal modulator. Nature Medicine, 
7(4), 414–415. https://doi.org/10.1038/86477 
Bennett, G. J., & Xie, Y.-K. (1988). A peripheral mononeuropathy in rat that produces 
disorders of pain sensation like those seen in man. Pain, 33(1), 87–107. 
https://doi.org/https://doi.org/10.1016/0304-3959(88)90209-6 
Benowitz, L. I., & Routtenberg, A. (1987). A membrane phosphoprotein associated with 
neural development, axonal regeneration, phospholipid metabolism, and synaptic 
plasticity. Trends in Neurosciences, 10(12), 527–532. 
https://doi.org/https://doi.org/10.1016/0166-2236(87)90135-4 
Benowitz, L. I., & Routtenberg, A. (1997). GAP-43: an intrinsic determinant of neuronal 
development and plasticity. Trends in Neurosciences, 20(2), 84–91. 
https://doi.org/10.1016/S0166-2236(96)10072-2 
Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., & Yaksh, T. L. (1994). 
Quantitative assessment of tactile allodynia in the rat paw. Journal of Neuroscience 
Methods, 53(1), 55–63. https://doi.org/https://doi.org/10.1016/0165-0270(94)90144-
9 
Chen, S.-H., Huang, T.-C., Wang, J.-Y., Wu, C.-C., & Hsueh, Y.-Y. (2020). Controllable 
 35 
forces for reproducible chronic constriction injury mimicking compressive 
neuropathy in rat sciatic nerve. Journal of Neuroscience Methods, 335, 108615. 
https://doi.org/https://doi.org/10.1016/j.jneumeth.2020.108615 
Cheong, H. R., Nguyen, N.-T., Khaw, M. K., Teoh, B. Y., & Chee, P. S. (2018). 
Wirelessly activated device with an integrated ionic polymer metal composite 
(IPMC) cantilever valve for targeted drug delivery. Lab on a Chip, 18(20), 3207–
3215. https://doi.org/10.1039/C8LC00776D 
Clatworthy, A. L., Illich, P. A., Castro, G. A., & Walters, E. T. (1995). Role of peri-
axonal inflammation in the development of thermal hyperalgesia and guarding 
behavior in a rat model of neuropathic pain. Neuroscience Letters, 184(1), 5–8. 
https://doi.org/https://doi.org/10.1016/0304-3940(94)11154-B 
Deuis, J. R., Dvorakova, L. S., & Vetter, I. (2017). Methods Used to Evaluate Pain 
Behaviors in Rodents   . Frontiers in Molecular Neuroscience  . Retrieved from 
https://www.frontiersin.org/article/10.3389/fnmol.2017.00284 
Gaudet, A. D., Popovich, P. G., & Ramer, M. S. (2011). Wallerian degeneration: Gaining 
perspective on inflammatory events after peripheral nerve injury. Journal of 
Neuroinflammation, 8(1), 110. https://doi.org/10.1186/1742-2094-8-110 
Huebner, E. a, & Strittmatter, S. M. (2009). Axon Regeneration in the Peripheral and 
Central Nervous Systems. Results and Problems in Cell Differentiation. Author 
Manuscript, 48, 339–351. https://doi.org/10.1007/400 
Janjic, J. M., Patel, S. K., Patrick, M. J., Pollock, J. A., DiVito, E., & Cascio, M. (2013). 
Suppressing inflammation from inside out with novel NIR visible perfluorocarbon 
nanotheranostics. In Proc.SPIE (Vol. 8596). Retrieved from 
 36 
https://doi.org/10.1117/12.2004625 
Janjic, J. M., Vasudeva, K., Saleem, M., Stevens, A., Liu, L., Patel, S., & Pollock, J. A. 
(2018). Low-dose NSAIDs reduce pain via macrophage targeted nanoemulsion 
delivery to neuroinflammation of the sciatic nerve in rat. Journal of 
Neuroimmunology, 318, 72–79. https://doi.org/10.1016/j.jneuroim.2018.02.010 
Ji, R.-R., Chamessian, A., & Zhang, Y.-Q. (2016). Pain regulation by non-neuronal cells 
and inflammation. Science (New York, N.Y.), 354(6312), 572–577. 
https://doi.org/10.1126/science.aaf8924 
Liu, L., Karagoz, H., Herneisey, M., Zor, F., Komatsu, T., Loftus, S., … Janjic, J. M. 
(2020). Sex Differences Revealed in a Mouse CFA Inflammation Model with 
Macrophage Targeted Nanotheranostics. Theranostics, 10(4), 1694–1707. 
https://doi.org/10.7150/thno.41309 
Lopez-Verrilli, M. A., Picou, F., & Court, F. A. (2013). Schwann cell-derived exosomes 
enhance axonal regeneration in the peripheral nervous system. Glia, 61(11), 1795–
1806. https://doi.org/10.1002/glia.22558 
Martin, M., Benzina, O., Szabo, V., Végh, A.-G., Lucas, O., Cloitre, T., … Gergely, C. 
(2013). Morphology and Nanomechanics of Sensory Neurons Growth Cones 
following Peripheral Nerve Injury. PLOS ONE, 8(2), e56286. Retrieved from 
https://doi.org/10.1371/journal.pone.0056286 
Montani, L., & Petrinovic, M. M. (2014). Targeting Axonal Regeneration: The Growth 
Cone Takes the Lead. The Journal of Neuroscience, 34(13), 4443 LP – 4444. 
https://doi.org/10.1523/JNEUROSCI.0320-14.2014 
Patel, S. K., & Janjic, J. M. (2015). Macrophage targeted theranostics as personalized 
 37 
nanomedicine strategies for inflammatory diseases. Theranostics, 5(2), 150–172. 
https://doi.org/10.7150/thno.9476 
Patel, S. K., Patrick, M. J., Pollock, J. A., & Janjic, J. M. (2013). Two-color fluorescent 
(near-infrared and visible) triphasic perfluorocarbon nanoemuslions. Journal of 
Biomedical Optics, 18(10), 101312. https://doi.org/10.1117/1.JBO.18.10.101312 
Patel, S. K., Zhang, Y., Pollock, J. A., & Janjic, J. M. (2013). Cyclooxgenase-2 inhibiting 
perfluoropoly (ethylene glycol) ether theranostic nanoemulsions-in vitro study. PloS 
One, 8(2), e55802–e55802. https://doi.org/10.1371/journal.pone.0055802 
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. del P., 
Acosta-Torres, L. S., … Shin, H.-S. (2018). Nano based drug delivery systems: 
recent developments and future prospects. Journal of Nanobiotechnology, 16(1), 71. 
https://doi.org/10.1186/s12951-018-0392-8 
Rambhia, K. J., & Ma, P. X. (2015). Controlled drug release for tissue engineering. 
Journal of Controlled Release : Official Journal of the Controlled Release Society, 
219, 119–128. https://doi.org/10.1016/j.jconrel.2015.08.049 
Ren, K., & Dubner, R. (2008). Neuron-glia crosstalk gets serious: role in pain 
hypersensitivity. Current Opinion in Anaesthesiology, 21(5), 570–579. 
https://doi.org/10.1097/ACO.0b013e32830edbdf 
Saleem, M., Deal, B., Nehl, E., Janjic, J. M., & Pollock, J. A. (2019). Nanomedicine-
driven neuropathic pain relief in a rat model is associated with macrophage polarity 
and mast cell activation. Acta Neuropathologica Communications, 7(1), 108. 
https://doi.org/10.1186/s40478-019-0762-y 
Saleem, M., Stevens, A. M., Deal, B., Liu, L., Janjic, J., & Pollock, J. A. (2019). A New 
 38 
Best Practice for Validating Tail Vein Injections in Rat with Near-infrared-Labeled 
Agents. JoVE, (146), e59295. https://doi.org/doi:10.3791/59295 
Skene, J. H., & Willard, M. (1981). Axonally transported proteins associated with axon 
growth in rabbit central and peripheral nervous systems. The Journal of Cell 
Biology, 89(1), 96–103. https://doi.org/10.1083/jcb.89.1.96 
Stevens, A. M., Liu, L., Bertovich, D., Janjic, J. M., & Pollock, J. A. (2019). Differential 
Expression of Neuroinflammatory mRNAs in the Rat Sciatic Nerve Following 
Chronic Constriction Injury and Pain-Relieving Nanoemulsion NSAID Delivery to 
Infiltrating Macrophages. International Journal of Molecular Sciences, 20(21), 
5269. https://doi.org/10.3390/ijms20215269 
Vasudeva, K., Andersen, K., Zeyzus-Johns, B., Hitchens, T. K., Patel, S. K., Balducci, 
A., … Pollock, J. A. (2014). Imaging neuroinflammation in vivo in a neuropathic 
pain rat model with near-infrared fluorescence and 19F magnetic resonance. PloS 
One, 9(2), e90589–e90589. https://doi.org/10.1371/journal.pone.0090589 
 
